Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Estimated costs of foodborne infections 140 million euros lower in 2020 In 2020, the estimated costs of foodborne infections in the Netherlands were 140 million euros lower than in the preceding year. This corresponds to a 30% decrease. ANP
Temporary background values for PFAS in Dutch soil RIVM has derived temporary background values for two types of PFAS in Dutch soil: PFOS (perfluorooctane sulfonate) and PFOA (perfluoro octanoic acid).
RIVM will calculate temporary background value for PFAS in soil In the coming weeks, RIVM will derive a temporary background value for PFAS in Dutch soil. This will be done based on measurement data from the provinces in the Netherlands.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Plant Protection Products: new RIVM methodology calculates period in which workers must wear gloves Commissioned by the Dutch Ministry of Social Affairs and Employment (SZW), RIVM has developed a new methodology to calculate the period for which workers must wear gloves to mitigate the risk of re
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.